

# Juan Morote

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3433610/publications.pdf>

Version: 2024-02-01

249  
papers

5,518  
citations

94433

37  
h-index

110387

64  
g-index

266  
all docs

266  
docs citations

266  
times ranked

6373  
citing authors

#	ARTICLE	IF	CITATIONS
1	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2012, 379, 39-46.	13.7	716
2	Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. <i>Journal of Urology</i> , 2007, 178, 1290-1295.	0.4	242
3	Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. <i>Journal of Clinical Oncology</i> , 2013, 31, 3800-3806.	1.6	196
4	Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer. <i>Urology</i> , 2007, 69, 500-504.	1.0	159
5	Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 625-632.	6.4	139
6	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. <i>Kidney International</i> , 2014, 85, 1161-1168.	5.2	126
7	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , 2011, 108, 24-30.	2.5	111
8	Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: Correlation with pathologic subtypes, p16INK4a expression, and prognosis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 73-82.	1.2	91
9	Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression. <i>Journal of Urology</i> , 2006, 175, 1679-1683.	0.4	90
10	Effect of Inflammation and Benign Prostatic Enlargement on Total and Percent Free Serum Prostatic Specific Antigen. <i>European Urology</i> , 2000, 37, 537-540.	1.9	87
11	PTOV1 Enables the Nuclear Translocation and Mitogenic Activity of Flotillin-1, a Major Protein of Lipid Rafts. <i>Molecular and Cellular Biology</i> , 2005, 25, 1900-1911.	2.3	86
12	Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. <i>Histology and Histopathology</i> , 2006, 21, 857-65.	0.7	80
13	Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. <i>Oncotarget</i> , 2017, 8, 4960-4976.	1.8	80
14	HAVCR/KIM-1 Activates the IL-6/STAT-3 Pathway in Clear Cell Renal Cell Carcinoma and Determines Tumor Progression and Patient Outcome. <i>Cancer Research</i> , 2014, 74, 1416-1428.	0.9	76
15	Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. , 1999, 84, 421-425.		67
16	Clinical Efficacy of Bone Alkaline Phosphatase and Prostate Specific Antigen in the Diagnosis of Bone Metastasis in Prostate Cancer. <i>Journal of Urology</i> , 1996, 155, 1348-1351.	0.4	66
17	Comparison of Percent Free Prostate Specific Antigen and Prostate Specific Antigen Density as Methods to Enhance Prostate Specific Antigen Specificity in Early Prostate Cancer Detection in Men With Normal Rectal Examination and Prostate Specific Antigen Between 4.1 and 10 ng./ml.. <i>Journal of Urology</i> . 1997, 158, 502-504.	0.4	64
18	Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer. <i>Urologia Internationalis</i> , 2006, 77, 135-138.	1.3	64

#	ARTICLE	IF	CITATIONS
19	PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. <i>Prostate</i> , 2010, 70, 1760-1767.	2.3	63
20	PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. <i>Oncogene</i> , 2001, 20, 1455-1464.	5.9	61
21	Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. <i>BJU International</i> , 2009, 103, 332-335.	2.5	58
22	Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of Treatment. <i>European Urology</i> , 2003, 44, 661-665.	1.9	56
23	The Present and Future of Prostate Cancer Urine Biomarkers. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12620-12649.	4.1	56
24	Metabolic syndrome increases the risk of aggressive prostate cancer detection. <i>BJU International</i> , 2013, 111, 1031-1036.	2.5	54
25	Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. <i>Cancer</i> , 1992, 70, 1974-1979.	4.1	53
26	Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. <i>International Journal of Cancer</i> , 2004, 108, 877-881.	5.1	50
27	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. <i>BJU International</i> , 2007, 99, 812-816.	2.5	50
28	PTOV-1, a Novel Protein Overexpressed in Prostate Cancer, Shuttles between the Cytoplasm and the Nucleus and Promotes Entry into the S Phase of the Cell Division Cycle. <i>American Journal of Pathology</i> , 2003, 162, 897-905.	3.8	49
29	Antiproliferative and apoptotic effects of the herbal agent <i>Pygeum africanum</i> on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). <i>Prostate</i> , 2010, 70, 1044-1053.	2.3	49
30	The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy. <i>Journal of Urology</i> , 2015, 193, 1963-1969.	0.4	49
31	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2020, 80, 4476-4486.	0.9	49
32	Value of Routine Transition Zone Biopsies in Patients Undergoing Ultrasound-Guided Sextant Biopsies for the First Time. <i>European Urology</i> , 1999, 35, 294-297.	1.9	48
33	PTOV1 Expression Predicts Prostate Cancer in Men with Isolated High-Grade Prostatic Intraepithelial Neoplasia in Needle Biopsy. <i>Clinical Cancer Research</i> , 2008, 14, 2617-2622.	7.0	48
34	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. <i>Current Oncology Reports</i> , 2011, 13, 216-221.	4.0	48
35	Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. <i>British Journal of Cancer</i> , 2015, 112, 468-474.	6.4	48
36	A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer. <i>Prostate</i> , 2011, 71, 1736-1745.	2.3	43

#	ARTICLE	IF	CITATIONS
37	Testosterone Measurement in Patients with Prostate Cancer. <i>European Urology</i> , 2010, 58, 65-74.	1.9	41
38	The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. <i>BJU International</i> , 2009, 104, 486-489.	2.5	40
39	Effects of Holmium Laser Enucleation of the Prostate on Sexual Function. <i>Journal of Endourology</i> , 2015, 29, 332-339.	2.1	39
40	Prediction of Prostate Volume Based on Total and Free Serum Prostate-Specific Antigen: Is It Reliable?. <i>European Urology</i> , 2000, 38, 91-95.	1.9	36
41	Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. <i>BJU International</i> , 2009, 104, 1637-1640.	2.5	36
42	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. <i>BJU International</i> , 2010, 105, 202-207.	2.5	36
43	Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. <i>Kidney International</i> , 2004, 65, 1761-1773.	5.2	32
44	Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. <i>BJU International</i> , 2011, 108, E71-6.	2.5	31
45	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. <i>British Journal of Cancer</i> , 2013, 108, 2565-2572.	6.4	31
46	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2017, 198, 817-823.	0.4	31
47	Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. <i>Experimental Cell Research</i> , 2009, 315, 3004-3013.	2.6	30
48	Improved Prediction of Biochemical Recurrence After Radical Prostatectomy by Genetic Polymorphisms. <i>Journal of Urology</i> , 2010, 184, 506-511.	0.4	28
49	Expression of Androgen, Oestrogen $\text{ER}\alpha$ and $\text{ER}\beta$ , and Progesterone Receptors in the Canine Prostate: Differences between Normal, Inflamed, Hyperplastic and Neoplastic Glands. <i>Journal of Comparative Pathology</i> , 2007, 136, 1-8.	0.4	26
50	Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients. <i>Urologia Internationalis</i> , 2013, 90, 41-44.	1.3	26
51	Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. <i>World Journal of Urology</i> , 2010, 28, 677-680.	2.2	25
52	Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13615-13623.	4.1	25
53	Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. <i>BJU International</i> , 2010, 105, 481-484.	2.5	24
54	Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. <i>European Journal of Cancer</i> , 2013, 49, 2034-2047.	2.8	23

#	ARTICLE	IF	CITATIONS
55	Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. <i>Prostate</i> , 2015, 75, 1102-1113.	2.3	23
56	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. <i>European Urology Oncology</i> , 2019, 2, 664-669.	5.4	23
57	PTOV1 is overexpressed in human high-grade malignant tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 323-330.	2.8	22
58	Measurement of free PSA in the diagnosis and staging of prostate cancer. , 1997, 71, 756-759.		21
59	Gastric Cancer in Augmentation Gastrocystoplasty. <i>Urologia Internationalis</i> , 2005, 74, 368-370.	1.3	21
60	Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. <i>BJU International</i> , 2014, 113, E164-77.	2.5	20
61	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. <i>Cancer</i> , 1996, 78, 2374-2378.	4.1	19
62	Intraindividual Variations of Total and Percent Free Serum Prostatic-Specific Antigen Levels in Patients with Normal Digital Rectal Examination. <i>European Urology</i> , 1999, 36, 111-115.	1.9	19
63	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010, 9, 675-691.	0.1	19
64	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. <i>British Journal of Cancer</i> , 2013, 109, 121-130.	6.4	19
65	Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	19
66	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. <i>Cancer Treatment Reviews</i> , 2016, 50, 208-216.	7.7	19
67	Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. <i>European Association of Urology</i> ; 2017. <a href="http://uroweb.org/guideline/prostate-cancer">http://uroweb.org/guideline/prostate-cancer</a> . <i>European Urology</i> , 2018, 73, e134-e135.	1.9	19
68	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. <i>Cancer Treatment Reviews</i> , 2020, 86, 102000.	7.7	19
69	Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. , 1998, 76, 464-467.		18
70	Definition of Castrate Resistant Prostate Cancer: New Insights. <i>Biomedicines</i> , 2022, 10, 689.	3.2	18
71	Genetic predisposition to early recurrence in clinically localized prostate cancer. <i>BJU International</i> , 2013, 111, 549-558.	2.5	17
72	Identification of somatic gene mutations in penile squamous cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 629-637.	2.8	17

#	ARTICLE	IF	CITATIONS
73	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 127-136.	4.4	17
74	Comparación de los resultados perioperatorios de la cistectomía radical asistida por robot con derivación urinaria extracorpórea vs. intracorpórea. <i>Actas Urológicas Españolas</i> , 2019, 43, 277-283.	0.7	17
75	Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. <i>Urology</i> , 2002, 59, 277-280.	1.0	16
76	Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer. <i>International Journal of Biological Markers</i> , 2005, 20, 209-216.	1.8	16
77	Prostate cancer in Spain: from guidelines to clinical practice. <i>BJU International</i> , 2011, 108, 61-66.	2.5	16
78	Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 655-663.	1.9	16
79	Maximal Testosterone Suppression in Prostate Cancer-Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	1.0	16
80	Sedentarismo y sobrepeso como factores de riesgo en la detección del cáncer de próstata y su agresividad. <i>Actas Urológicas Españolas</i> , 2014, 38, 232-237.	0.7	16
81	Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies. <i>Prostate</i> , 2016, 76, 1501-1506.	2.3	16
82	The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/ml. <i>European Urology</i> , 2002, 42, 333-337.	1.9	15
83	Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>Eur Urol</i> 2008;54:303-14. <i>European Urology</i> , 2009, 55, e15-e16.	1.9	15
84	Preoperative Prediction of Pathologically Insignificant Prostate Cancer in Radical Prostatectomy Specimens: The Role of Prostate Volume and the Number of Positive Cores. <i>Urologia Internationalis</i> , 2010, 84, 153-158.	1.3	15
85	Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e491-e496.	1.9	15
86	Low-dose statin treatment increases prostate cancer aggressiveness. <i>Oncotarget</i> , 2018, 9, 1494-1504.	1.8	15
87	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 59165-59180.	1.8	15
88	Effect of High-Grade Prostatic Intraepithelial Neoplasia on Total and Percent Free Serum Prostatic-Specific Antigen. <i>European Urology</i> , 2000, 37, 456-459.	1.9	14
89	The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. <i>BJU International</i> , 2001, 83, 1003-1006.	2.5	14
90	Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies. <i>Prostate</i> , 2015, 75, 1669-1675.	2.3	14

#	ARTICLE	IF	CITATIONS
91	Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. <i>International Journal of Urology</i> , 2016, 23, 957-958.	1.0	14
92	Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 590-594.	0.8	14
93	Valor de la proteína STAT3 como factor pronóstico en el carcinoma renal de célula clara. Revisión sistemática. <i>Actas Urológicas Españolas</i> , 2019, 43, 118-123.	0.7	14
94	M-CAVI, A Neoadjuvant Carboplatin-based Regimen for the Treatment of T2-4N0M0 Carcinoma of the Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 344-348.	1.3	14
95	Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. <i>Journal of Urology</i> , 1996, 155, 1348-51.	0.4	14
96	Use of Percent Free Prostate-Specific Antigen as a Predictor of the Pathological Features of Clinically Localized Prostate Cancer. <i>European Urology</i> , 2000, 38, 225-229.	1.9	13
97	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 863-866.	1.4	13
98	A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. <i>European Urology Oncology</i> , 2022, 5, 460-463.	5.4	13
99	The Barcelona Predictive Model of Clinically Significant Prostate Cancer. <i>Cancers</i> , 2022, 14, 1589.	3.7	13
100	Avances en la prevención y el tratamiento de las metástasis óseas en cáncer de próstata. Papel de la inhibición de RANK/RANKL. <i>Actas Urológicas Españolas</i> , 2013, 37, 292-304.	0.7	12
101	Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues. <i>BioMed Research International</i> , 2013, 2013, 1-15.	1.9	12
102	Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. <i>Scandinavian Journal of Urology</i> , 2016, 50, 425-428.	1.0	12
103	Eficacia del Índice de salud prostática para identificar cánceres de próstata agresivos. Una validación institucional. <i>Actas Urológicas Españolas</i> , 2016, 40, 378-385.	0.7	12
104	Reversal Unilateral Ureteral Obstruction: A Mice Experimental Model. <i>Nephron</i> , 2019, 142, 125-134.	1.8	12
105	Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 886.	3.7	12
106	Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. <i>Journal of Clinical Oncology</i> , 2012, 30, 6-6.	1.6	12
107	Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate. <i>BMC Molecular Biology</i> , 2009, 10, 59.	3.0	11
108	Immunolocalization of Androgen Receptors, Estrogen Receptors, and Estrogen Receptors in Experimentally Induced Canine Prostatic Hyperplasia. <i>Journal of Andrology</i> , 2009, 30, 240-247.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Extensive emphysematous pyelonephritis in a renal allograft: case report and review of literature. <i>Transplant Infectious Disease</i> , 2014, 16, 642-647.	1.7	11
110	Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressiveness. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 232-237.	0.2	11
111	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 128.	2.7	11
112	Revisión sistemática de los factores pronósticos del carcinoma renal. <i>Actas Urológicas Españolas</i> , 2017, 41, 215-225.	0.7	11
113	La resonancia magnética preoperatoria predice la recuperación temprana de la continencia urinaria tras la prostatectomía radical robótica. <i>Actas Urológicas Españolas</i> , 2019, 43, 137-142.	0.7	11
114	Under-expression of CK2 <sup>β</sup> subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. <i>Oncotarget</i> , 2018, 9, 5736-5751.	1.8	11
115	Determinación de la testosterona sérica durante la supresión androgénica en pacientes con cáncer de próstata: una revisión sistemática. <i>Actas Urológicas Españolas</i> , 2016, 40, 477-484.	0.7	10
116	Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 168-173.	2.2	10
117	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 410-417.	1.6	10
118	Variaciones de la prostatectomía radical para una recuperación de la continencia urinaria precoz: una revisión sistemática. <i>Actas Urológicas Españolas</i> , 2019, 43, 526-535.	0.7	10
119	Influence of high-grade prostatic intraepithelial neoplasia on total and percentage free serum prostatic specific antigen. <i>BJU International</i> , 1999, 84, 657-660.	2.5	9
120	Behavior of free Testosterone in Patients with Prostate Cancer on Androgen Deprivation Therapy. <i>International Journal of Biological Markers</i> , 2005, 20, 119-122.	1.8	9
121	Comportamiento de la testosterona total y libre en suero como predictores del riesgo de cáncer de próstata y de su agresividad. <i>Actas Urológicas Españolas</i> , 2015, 39, 573-581.	0.7	9
122	Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. <i>Prostate</i> , 2017, 77, 114-120.	2.3	9
123	The role of prostate tumor overexpressed 1 in cancer progression. <i>Oncotarget</i> , 2017, 8, 12451-12471.	1.8	9
124	Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. <i>Journal of Urology</i> , 1997, 158, 502-4.	0.4	9
125	Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFR mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. , 1998, 76, 519-522.		8
126	Is there a relationship between prostate volume and Gleason score?. <i>BJU International</i> , 2008, 102, 563-565.	2.5	8



#	ARTICLE	IF	CITATIONS
127	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015, 115, 364-372.	2.5	8
128	siRNA-silencing of CD40 attenuates unilateral ureteral obstruction-induced kidney injury in mice. <i>PLoS ONE</i> , 2019, 14, e0215232.	2.5	8
129	The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer. <i>World Journal of Men's Health</i> , 2022, 40, 270.	3.3	8
130	Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples. <i>Cancers</i> , 2021, 13, 6202.	3.7	8
131	A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model. <i>Prostate</i> , 2010, 70, 1402-1412.	2.3	7
132	Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. <i>Actas Urológicas Españolas (English Edition)</i> , 2013, 37, 292-304.	0.2	7
133	Significado clínico de la atrofia proliferativa inflamatoria en la biopsia prostática. <i>Actas Urológicas Españolas</i> , 2014, 38, 122-126.	0.7	7
134	Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?. <i>Clinical and Translational Oncology</i> , 2014, 16, 102-106.	2.4	7
135	Role of Immunotherapy in Castration-Resistant Prostate Cancer (<scp>CRPC</scp>). <i>BJU International</i> , 2014, 113, 367-375.	2.5	7
136	Función cognitiva en pacientes tratados con supresión androgénica: estudio prospectivo y multicéntrico. <i>Actas Urológicas Españolas</i> , 2018, 42, 114-120.	0.7	7
137	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. <i>International Journal of Biological Markers</i> , 2005, 20, 119-222.	1.8	7
138	Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4510-4510.	1.6	7
139	Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 273-281.	3.8	7
140	Bone Marrow Prostatic Specific Antigen and Prostatic Acid Phosphatase Levels: Are They Helpful in Staging Prostatic Cancer. <i>Journal of Urology</i> , 1987, 137, 891-893.	0.4	6
141	Case report: Retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma. <i>International Urology and Nephrology</i> , 2006, 38, 463-465.	1.4	6
142	Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. <i>Clinical and Translational Oncology</i> , 2010, 12, 346-355.	2.4	6
143	Papel del antígeno prostático específico ante las nuevas evidencias científicas. <i>Actas Urológicas Españolas</i> , 2013, 37, 324-329.	0.7	6
144	Cambios hormonales después del tratamiento de cáncer de próstata localizado. Comparación entre radioterapia de haz externo y prostatectomía radical. <i>Actas Urológicas Españolas</i> , 2016, 40, 549-555.	0.7	6

#	ARTICLE	IF	CITATIONS
145	Utilidad del Índice RENAL "Radius; Exo/endophytic; Nearness to sinus; Anterior/posterior; Location relative to polar lines" en el manejo de las masas renales. <i>Actas Urológicas Españolas</i> , 2016, 40, 601-607.	0.7	6
146	Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years. <i>Urologia Internationalis</i> , 2019, 102, 277-283.	1.3	6
147	Comparison of standard vs. palliative management for bladder cancer in patients older than 85 years: multicenter study of 317 de novo tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 40.e9-40.e15.	1.6	6
148	How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies. <i>World Journal of Urology</i> , 2020, 38, 1481-1491.	2.2	6
149	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. <i>BMC Urology</i> , 2020, 20, 99.	1.4	6
150	Individual variations of total and percent free serum prostatic specific antigen: could they change the indication of prostatic biopsy?. <i>Oncology Reports</i> , 1999, 6, 887-90.	2.6	6
151	Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy. <i>World Journal of Men's Health</i> , 2022, 40, 74.	3.3	6
152	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. <i>International Journal of Biological Markers</i> , 2002, 17, 239-243.	1.8	5
153	Ultrastructural Changes in Prostate Cells During Hormone-induced Canine Prostatic Hyperplasia. <i>Ultrastructural Pathology</i> , 2006, 30, 435-442.	0.9	5
154	Estado actual del trasplante renal en bloque de donante pediátrico en receptor adulto joven. <i>Actas Urológicas Españolas</i> , 2013, 37, 383-386.	0.7	5
155	Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. <i>Actas Urológicas Españolas (English Edition)</i> , 2016, 40, 477-484.	0.2	5
156	Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients. <i>Journal of Biomedical Science</i> , 2017, 24, 81.	7.0	5
157	The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. <i>Actas Urológicas Españolas (English Edition)</i> , 2019, 43, 118-123.	0.2	5
158	Re: Frank-Jan H. Drost, Daniel Osses, Daan Nieboer, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. <i>Eur Urol</i> 2020;77:78-94. <i>European Urology</i> , 2020, 77, e138-e139.	1.9	5
159	Papel del antígeno prostático específico ante las nuevas evidencias científicas, una nueva actualización en 2020. <i>Actas Urológicas Españolas</i> , 2021, 45, 21-29.	0.7	5
160	Impact of immune-related adverse events on survival in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 4531-4531.	1.6	5
161	Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. <i>International Journal of Biological Markers</i> , 2002, 17, 239-243.	1.8	5
162	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category. <i>European Urology Open Science</i> , 2022, 37, 38-44.	0.4	5

#	ARTICLE	IF	CITATIONS
163	Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy. <i>International Journal of Biological Markers</i> , 2005, 20, 119-22.	1.8	5
164	Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer. <i>Cancers</i> , 2022, 14, 1828.	3.7	5
165	Elevated serum PSA and acute bacterial prostatitis. <i>Urology</i> , 1990, 35, 373.	1.0	4
166	Correlation Between the Biopsies in Marginal Donor Kidneys for Transplantation: Is It Necessary to Biopsy Both Kidneys?. <i>Transplantation Proceedings</i> , 2006, 38, 1270-1273.	0.6	4
167	Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 232-239.	0.2	4
168	33% radius evaluation to assess bone mineral density in prostate cancer patients. <i>World Journal of Urology</i> , 2011, 29, 815-819.	2.2	4
169	Significado actual del hallazgo de la neoplasia intraepitelial prostática de alto grado en la biopsia prostática. <i>Actas Urológicas Españolas</i> , 2014, 38, 270-275.	0.7	4
170	Síndrome metabólico en pacientes con cáncer de próstata sometidos a supresión androgénica. <i>Actas Urológicas Españolas</i> , 2014, 38, 285-289.	0.7	4
171	Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. <i>European Urology Focus</i> , 2017, 3, 470-479.	3.1	4
172	Estado actual de la ingeniería tisular aplicada a la reconstrucción vesical en humanos. <i>Actas Urológicas Españolas</i> , 2018, 42, 435-441.	0.7	4
173	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. <i>Scandinavian Journal of Urology</i> , 2019, 53, 21-25.	1.0	4
174	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. <i>Scientific Reports</i> , 2020, 10, 20135.	3.3	4
175	Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC). <i>Scientific Reports</i> , 2021, 11, 6957.	3.3	4
176	The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial. <i>European Journal of Radiology</i> , 2021, 137, 109589.	2.6	4
177	The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia. <i>BJU International</i> , 2022, 129, 627-633.	2.5	4
178	Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions. <i>European Urology</i> , 2022, 81, 124-125.	1.9	4
179	Skeletal complications of ADT: disease burden and treatment options. <i>Asian Journal of Andrology</i> , 2012, 14, 670-675.	1.6	4
180	Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata. <i>Actas Urológicas Españolas</i> , 2020, 44, 156-163.	0.7	4

#	ARTICLE	IF	CITATIONS
181	Surgeon preimplantation macroscopic graft appraisal improves risk stratification of deceased kidney donors: a prospective study. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	4
182	Bone Alkaline Phosphatase Serum Level Predicts the Response to Antiandrogen Withdrawal. <i>European Urology</i> , 2002, 41, 257-261.	1.9	3
183	Analysis of Bone Alkaline Phosphatase as a Marker for the Diagnosis of Osteoporosis in Men under Androgen Ablation. <i>International Journal of Biological Markers</i> , 2003, 18, 290-294.	1.8	3
184	25 THE SERUM TESTOSTERONE CASTRATION LEVEL WITH CLINICAL RELEVANCE. <i>European Urology Supplements</i> , 2007, 6, 29.	0.1	3
185	Recommendations on the management of controversies in advanced castrate-resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2012, 36, 569-577.	0.2	3
186	Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 270-275.	0.2	3
187	Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. <i>Rheumatology International</i> , 2014, 34, 1419-1425.	3.0	3
188	Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. <i>Actas Urológicas Españolas (English Edition)</i> , 2015, 39, 573-581.	0.2	3
189	Radiofrecuencia percutánea guiada por ecografía en el tratamiento de masas renales pequeñas. <i>Actas Urológicas Españolas</i> , 2017, 41, 497-503.	0.7	3
190	Métodos para cuantificar la testosterona sérica en pacientes con cáncer de próstata sometidos a castración: una revisión sistemática. <i>Actas Urológicas Españolas</i> , 2018, 42, 86-93.	0.7	3
191	Las biopsias de próstata dirigidas ¿están listas para reemplazar las biopsias de próstata sistemáticas?. <i>Actas Urológicas Españolas</i> , 2019, 43, 573-578.	0.7	3
192	Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 230-235.	1.9	3
193	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.4	3
194	Definición de continencia y factores pronósticos para la recuperación temprana de la continencia urinaria en la prostatectomía radical robótica con reconstrucción posterior del rabdoesfínter. Análisis post hoc de un ensayo clínico aleatorizado. <i>Actas Urológicas Españolas</i> , 2022, 46, 159-166.	0.7	3
195	Behavior of Bone Alkaline Phosphatase (BAP) Determined with Immunoradiometric Assay in Metastatic Prostate Cancer. <i>International Journal of Biological Markers</i> , 1994, 9, 145-145.	1.8	2
196	Antihypertensive Drugs and the Risk of Prostate Cancer. <i>European Urology</i> , 2011, 60, 1309-1310.	1.9	2
197	Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. <i>Eur Urol</i> 2012;61:378-84. <i>European Urology</i> , 2012, 61, e53-e54.	1.9	2
198	The role of prostate-specific antigen in light of new scientific evidence. <i>Actas Urológicas Españolas (English Edition)</i> , 2013, 37, 324-329.	0.2	2

#	ARTICLE	IF	CITATIONS
199	Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 285-289.	0.2	2
200	A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells. <i>Cancer Letters</i> , 2019, 452, 158-167.	7.2	2
201	Re: Lars Boesen, Nis NÅrgaard, Vibeke LÅgager, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7â€“10 Prostate Cancer in Biopsy-naÅve Men. <i>Eur Urol Oncol</i> 2019;2:311â€“9. <i>European Urology Oncology</i> , 2020, 3, 392-393.	5.4	2
202	Valor actual de los hallazgos histolÃ³gicos de biopsias de prÃ³stata negativas en la predicciÃ³n del riesgo futuro de cÃ¡ncer de prÃ³stata clÃnicamente significativo. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2021, 45, 447-454.	0.7	2
203	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 551-551.	1.6	2
204	Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 500-500.	1.6	2
205	Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration. <i>European Urology Open Science</i> , 2020, 19, 24-26.	0.4	2
206	Who with suspected prostate cancer can benefit from ProclariX after multiparametric magnetic resonance imaging?. <i>International Journal of Biological Markers</i> , 2022, 37, 218-223.	1.8	2
207	Comparison of ProclariX, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. <i>Cancers</i> , 2022, 14, 2702.	3.7	2
208	Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659â€“68. <i>European Urology</i> , 2010, 57, e1.	1.9	1
209	858 AXIAL VERSUS PERIPHERAL DXA SCAN TO ASSES OSTEOPOROSIS IN PROSTATE CANCER PATIENTS. <i>Journal of Urology</i> , 2010, 183, .	0.4	1
210	2321 COMPARATIVE ANALYSIS OF PROSTATE CANCER ANTIGEN 3 MRNA EXPRESSION IN BENIGN PERIPHERAL PROSTATIC TISSUE, CANCER AND ISOLATED OR CANCER-ASSOCIATED HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA. <i>Journal of Urology</i> , 2011, 185, .	0.4	1
211	Bone health in patients with prostate cancer. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2014, 38, 685-693.	0.2	1
212	UreteropielostomÃa con vÃa nativa en el tratamiento de la uropatÃa obstructiva en el trasplante renal adulto. Experiencia y posibilidades tÃcnicas. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2014, 38, 552-556.	0.7	1
213	Salud Ãsea en pacientes con cÃ¡ncer de prÃ³stata. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2014, 38, 685-693.	0.7	1
214	A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2018, 42, 86-93.	0.2	1
215	Use of an acellular collagenâ€“elastin matrix to support bladder regeneration in a porcine model of peritoneocystoplasty. <i>Central European Journal of Urology</i> , 2018, 71, 353-359.	0.3	1
216	Multiple immunofluorescence assay identifies upregulation of Active Î²-catenin in prostate cancer. <i>BMC Research Notes</i> , 2019, 12, 68.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Are Multiparametric Magnetic Resonance Imaging and Guided Biopsies Needed in Men with Normal Digital Rectal Examination and Prostatic-specific Antigen >20â€%ng/ml?. <i>European Urology Oncology</i> , 2021, 4, 334-335.	5.4	1
218	Reply to Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, and Henk van der Poelâ€™s Letter to the Editor re: Aina Salazar, Lucas Regis, Jacques Planas, et al. A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. <i>Eur Urol Oncol</i> . In press. <a href="https://doi.org/10.1016/j.euo.2021.02.005">https://doi.org/10.1016/j.euo.2021.02.005</a> . <i>European Urology Oncology</i> , 2021, , .	5.4	1
219	The role of prostate-specific antigen in light of new scientific evidence: An update in 2020. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2021, 45, 21-29.	0.2	1
220	Prostate carcinoma staging: Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. <i>Cancer</i> , 1996, 78, 2374-2378.	4.1	1
221	Measurement of free PSA in the diagnosis and staging of prostate cancer. <i>International Journal of Cancer</i> , 1997, 71, 756-759.	5.1	1
222	PÃ©rdida de masa Ã³sea en pacientes con cÃ¡ncer de prÃ³stata sometidos a deprivaciÃ³n androgÃ©nica. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2011, 35, .	0.7	1
223	Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation. <i>Central European Journal of Urology</i> , 2019, 72, 92-99.	0.3	1
224	AnÃ¡lisis de la expresiÃ³n nuclear de pSer727-STAT3 como factor pronÃ³stico en pacientes con carcinoma renal de cÃ©lulas claras. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2020, 44, 245-250.	0.7	1
225	Re: Magdalena GÃ¼rtz, Jan Philipp Radtke, Gencay Hatiboglu, et al. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. <i>Eur Urol Focus</i> 2021;7:325â€“31. <i>European Urology Focus</i> . 2022,...	3.1	1
226	Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. <i>Cancer</i> , 1996, 78, 2374-8.	4.1	1
227	Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. <i>Cancers</i> , 2022, 14, 2374.	3.7	1
228	The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy. <i>European Urology Open Science</i> , 2022, 42, 40-41.	0.4	1
229	Impact of kidney and liver metabolism on serum prostate specific antigen levels. <i>International Journal of Biological Markers</i> , 1995, 10, 236-237.	1.8	0
230	Value of Percent Free Prostate-Specific Antigen for the Prediction of Pathological Stage in Men with Clinically Localized Prostate Cancer. <i>International Journal of Biological Markers</i> , 2002, 17, 239-243.	1.8	0
231	Re: Endo et al.: Anteroposterior Dissection HoLEP: A Modification to Prevent Transient Stress Urinary Incontinence ( <i>Urology</i> 2010;76:1451-1455). <i>Urology</i> , 2011, 77, 255-256.	1.0	0
232	CÃ¡ncer de prÃ³stata resistente a castraciÃ³n no diseminado (CPRCM0), un viejo escenario con interÃ©s clÃnico renovado. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2014, 38, 419-420.	0.7	0
233	Systematic review of renal carcinoma prognostic factors. <i>Actas UrolÃ³gicas EspaÃ±olas (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	0
234	Replay by authors: Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 571.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Estudio comparativo de diferentes técnicas quirúrgicas para el manejo del uréter distal durante la nefroureterectomía laparoscópica. <i>Actas Urológicas Españolas</i> , 2019, 43, 543-550.	0.7	0
236	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 39, 432.e11-432.e19.	1.6	0
237	Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 245-250.	0.2	0
238	Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 156-163.	0.2	0
239	Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 343-345.	0.4	0
240	The current value of histological findings in negative prostate biopsies to predict the future risk of clinically significant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 447-454.	0.2	0
241	Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation. <i>International Journal of Biological Markers</i> , 2003, 18, 290-294.	1.8	0
242	Holmium Laser Enucleation of the Prostate. <i>Videourology (New Rochelle, N Y)</i> , 2012, 26, .	0.1	0
243	C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16045-e16045.	1.6	0
244	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15627-e15627.	1.6	0
245	The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-496.	1.6	0
246	The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2022, , .	0.6	0
247	Continenence definition and prognostic factors for early urinary continence recovery in posterior rhabdosphincter reconstruction after robot-assisted radical prostatectomy. Post-hoc analysis of a randomised controlled trial. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, , .	0.2	0
248	Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review. <i>BMC Cancer</i> , 2022, 22, 357.	2.6	0
249	Cuantificación de la isoforma compleja del antígeno prostático específico (PSAc). Un nuevo reto en la era PSA. <i>Medicina Clínica</i> , 2004, 122, 256-258.	0.6	0